New Study Reveals Global Intravenous (I.V.) Iron Drugs Market Analysis and Outlook 2015

Researchmoz added Most up-to-date research on "Global Intravenous (I.V.) Iron Drugs Market Report: 2015 Edition" to its huge collection of research reports.

Iron deficiency anemia is the most common form of anemia throughout the world. It is estimated that two billion people suffer from iron deficiency anemia worldwide. To address iron deficiency, iron therapy is important being the critical factor in the production of red blood cells. Around 4.5 million Americans are diagnosed and suffering from iron deficiency anemia (IDA).

Generally, daily oral iron is the first line therapy for most IDA patient but for many patients oral iron therapy fails as a consequence of compliance, efficacy and side effects like constipation and gastro intestinal disorders. When oral supplements fail to meet the requirement, intravenous (I.V.) iron therapy is used, in which iron is directly injected with a needle into a vein. Iron given intravenously allows larger amounts of iron to be provided to patients while avoiding many of the side effects and treatment compliance issues associated with oral iron, and can result in faster rises in hemoglobin levels. In the US, a small fraction of non-dialysis CKD patients who are diagnosed with IDA are currently being treated with I.V. iron, and thus a significant opportunity is there for the market.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=285761

The key factors driving growth of the global I.V. iron industry include iron deficiency in hemodialysis patient cases, growing number of ERSD patients, prevalence of iron deficiency in women, increasing global healthcare expenditure, increasing global ageing population and large potential in new therapeutic areas. Some of the noteworthy trends and developments of this industry are penetration of I.V. iron in obstetrics and gynecology area, new product development and increase in awareness of disease. However, the growth of this sector is hindered by potential risks of using I.V. iron, emerging anemia management therapies and strict regulatory structures.

The report provides a comprehensive study of iron product market and I.V. iron market globally. It also provides detailed information for key regional markets of I.V iron industry. The competition in the global I.V. iron market is stiff among large players like Galenica Group, AMAG Pharmaceuticals Inc. and Actavis Plc. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.

Table of Content

1. Overview1.1 I.V. Iron Application Areas
1.1.1 I.V. Iron Application in Nephrology
1.2 Iron Deficiency - Anemia
1.2.2 Iron Deficiency Metrics
1.3 I.V. Iron Therapies for Anemia Treatment

2. Market Analysis
2.1 Global Iron Product Market

- Market Value
- Market Segments

2.2.1 Global I.V. Iron Drug Market

- Market Value
- Product Share

2.2 Regional Analysis
2.2.1 The US I.V. Iron Drug Market

- Market Value
- Product Share
- Non-Dialysis IV Iron Market

2.2.2 European I.V. Iron Drug Market

- Market Value
- Product Share

2.2.3 Australian I.V. iron Drug Market

- Market Value
- Product Share

3. Market Dynamics
3.1 Growth Drivers
3.1.1 Iron Deficiency in Hemodialysis Patients Cases
3.1.2 Growing Number of ERSD Patients
3.1.3 Prevalence of Iron Deficiency in Women
3.1.4 Increasing Global Healthcare Expenditure
3.1.5 Increasing Global Ageing Population
3.1.6 Large Potential in New Therapeutic Areas
3.2 Key Trends
3.2.1 I.V. Iron Penetration in Obstetrics and Gynecology Area
3.2.2 New Product Development
3.2.3 Increase Disease Awareness
3.3 Challenges
3.3.1 Potential Risks of I.V. Iron
3.3.2 Emerging Anemia Management Therapies
3.3.3 Strict Regulatory Structures

4. Competitive Landscape
4.1 Global Market
4.2 Regional Market
4.2.1 The US
4.2.2 Europe
4.3 Product Comparison

5. Company Profiles
5.1 Galenica group
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies

- Executing an Iron Deficiency Franchise
- Exploit the Commercial Potential

5.2 AMAG Pharmaceuticals
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies

- Capture a Larger Market Share
- Feraheme in Non-Dialysis Adult CKD Patients

5.3 Actavis Plc
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies

- Development through Mergers & Acquisitions
- Differentiated and High-Demand Products

6. Market Outlook
6.1 Market Forecast
6.2 Forecast Methodology
6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=285761

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
Follow us on LinkedIn @ http://bit.ly/1TBmnVG

This release was published on openPR.